VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, ...

The company recently wowed investors with clinical trial results.

They have at least one thing in common: An exciting pipeline.

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...